1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole

Are you looking for trusted manufacturer or supplier of CAS:73963-42-5 1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole? Why not just drop an inquiry to info@nbinno.com or visit www.nbinno.com our official website?


1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole manufacturer in India China

Chemical Name:1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole
CAS.NO:73963-42-5
Synonyms:1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole
5-(4-Chlorobutyl)-1-cyclohexanyl tetrazole
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 425.2±24.0 °C at 760 mmHg
Melting Point 49-52°C
Molecular Formula C11H19ClN4
Molecular Weight 242.748
Flash Point 210.9±22.9 °C
 
Specification:
Appearance:White to off-white powder
Assay:≥99.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Cilostazol(CAS:73963-72-1).



1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole Certificate of analysis (COA),5-(4-Chlorobutyl)-1-cyclohexanyl tetrazole Specification,1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole Safety Data Sheet (MSDS),1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole NMR,1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole Route of synthesis (ROS),1-Cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole Method of Anasis (MOA)


Related News: In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.N-[(S)-Ethoxycarbonyl-1-Butyl]-(S)-Alanine manufacturer As one of the world’s largest API producers and exporters, China’s chemical API production and operating income show steady growth.Allyl bromide CAS:106-95-6 supplier The StartScore model was developed by the company’s in-house supply chain experts based on actual performance data.clorhidrato de etil (3S, 4R) -4-amino-3-metoxipiperidina-1-carboxilato CAS:83863-71-2 producer The StartScore model was developed by the company’s in-house supply chain experts based on actual performance data.As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.